24/7 Market News Snapshot 10 December, 2024 – Cardiff Oncology, Inc. Common Stock (NASDAQ:CRDF)

December 10, 2024

DENVER, Colo., 10 December, 2024 (247marketnews.com) – (NASDAQ:CRDF) are discussed in this article.
Cardiff Oncology, Inc. (CRDF) has witnessed notable market activity, with its stock price surging by 27.25% to reach $3.105 in pre-market trading, significantly up from the previous close of $2.440. The company experienced a trading volume of 1.61 million shares, reflecting heightened investor enthusiasm and signaling potential for further growth. This strong bullish trend has generated considerable interest among investors, presenting an attractive opportunity for those looking to take advantage of its upward trajectory.

In conjunction with the encouraging market performance, Cardiff Oncology also announced promising initial results from its CRDF-004 randomized Phase 2 clinical trial. This study evaluates the safety and efficacy of their lead candidate, onvansertib, in combination with standard-of-care therapies for patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). The preliminary results revealed a notable increase in the objective response rate (ORR) among patients receiving the 30 mg dose of onvansertib, with 64% achieving a response, compared to just 33% in the control group receiving standard therapy. Additionally, the 30 mg dosage demonstrated a superior profile over the 20 mg dose (64% vs. 50% ORR), indicating significant tumor regression.

Dr. Fairooz Kabbinavar, Chief Medical Officer of Cardiff Oncology, emphasized the potential transformative impact of onvansertib for the nearly 50,000 newly diagnosed RAS-mutated mCRC patients each year. With a favorable safety profile across both dosing regimens and no major safety concerns reported, the trial is continuing to recruit eligible patients with documented KRAS or NRAS mutations. Cardiff Oncology plans to release further clinical data in the first half of 2025 and will hold a conference call today at 8:00 a.m. ET to discuss these developments, marking a significant advancement in the company’s efforts to develop effective cancer therapies.

Related news for (CRDF)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.